STLN NASDAQ
Starling Oncology, Inc.
1W: -2.6%
1M: -5.6%
3M: +27.1%
YTD: +71.4%
1Y: +36.4%
3Y: +305.8%
5Y: -36.8%
$6.59
+0.30 (+4.77%)
Weekly Expected Move ±8.3%
$6
$6
$7
$7
$8
Credit Risk of going bust: lower than 99% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.00 (down more than 99.9%), Starling Oncology, Inc. would be worth roughly what it owes.
Total debt $90K against a stock market value of $436.4M.
Distance to default 34.48 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $87K (short-term plus half of long-term), stock volatility 24.7%; Altman Z'' -5.23. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Total debt $90K against a stock market value of $436.4M.
Distance to default 34.48 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $87K (short-term plus half of long-term), stock volatility 24.7%; Altman Z'' -5.23. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$628.9M
52W Range2.32-7.13
Volume1,858,841
Avg Volume1,512,816
Beta0.42
Dividend—
Analyst Ratings
Company Info
CEODaniel Virnich
Employees641
SectorHealthcare
IndustryMedical - Care Facilities
IPO Date2026-08-04
Websitestarlingoncology.com
18000 Studebaker Road, Suite 800
Cerritos, CA 90703
US
Cerritos, CA 90703
US
About Starling Oncology, Inc.
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Hively Brad | S-Sale | 298,853 | $6.51 | 2026-08-21 |
| Chernett Jorey | P-Purchase | 12,000 | $6.54 | 2026-08-14 |
| Chernett Jorey | S-Sale | 100 | $9.00 | 2026-08-13 |